Latest Insights - page 43 | BiopharmaTrend

Eli Lilly Partners with UK’s Alchemab to Develop New ALS Antibodies

Eli Lilly has partnered with UK-based biotech Alchemab Therapeutics to develop therapeutic antibodies targeting amyotrophic lateral sclerosis (ALS), a neurodegenerative disease with limited treatment options. The agreement comes during a …

Continue ›››

What CROs Cite as Their Top Clinical Trial Challenges and How They Plan to Overcome Them in 2025

In a rapidly evolving clinical research landscape, there is a greater need now more than ever for pharma and biotech companies to outsource trial management activities to contract research organizations …

Continue ›››

Discovery of Novel Longevity Therapeutics that Target Mitochondrial Enzymes

Researchers at CCM Biosciences, a New Jersey-based biopharmaceutical company, have reported the discovery of first-in-class compounds designed to restore the activity of SIRT3, a mitochondrial enzyme critical to cellular energy …

Continue ›››

Merck KGaA Adopts Quris-AI’s Organ-On-Chip Platform for Preclinical Drug Safety Testing

Merck KGaA has integrated Quris-AI’s Bio-AI platform into its drug development pipeline to evaluate small molecule drug candidates for safety before clinical trials. The collaboration builds on a two-year validation …

Continue ›››

PostEra and Pfizer Expand $610M Partnership for AI-Driven ADC Development

PostEra, Boston biotech specializing in AI-driven drug discovery, announced an expansion of its collaboration with Pfizer, increasing the total partnership value to $610 million. This includes a new initiative focused …

Continue ›››

Tempus and Genialis Partner on RNA-Based Biomarker Algorithms

Tempus AI has partnered with Genialis to develop RNA-based biomarker algorithms aimed at improving cancer diagnostics and treatment outcomes. This collaboration allows Genialis to use Tempus’ multimodal dataset, one of …

Continue ›››

Novo Nordisk and Valo Health Expand AI Collaboration for Cardiometabolic Drug Discovery

Novo Nordisk has deepened its partnership with Valo Health, increasing the scope of their collaboration to include up to 20 drug programs targeting obesity, type 2 diabetes, and cardiovascular disease. …

Continue ›››

Recursion Advances Two Investigational Oncology Drugs to Clinical Trials

Recursion Pharmaceuticals announced the progression of two investigational oncology drugs, REC-3565 and REC-4539, into clinical trials, targeting critical unmet needs in hematologic malignancies and small-cell lung cancer (SCLC). Both therapies …

Continue ›››

Neumora’s Kappa Opioid Antagonist Falters in Phase 3 Depression Trial

Neumora Therapeutics’ lead drug, navacaprant, failed to show efficacy in the Phase 3 "KOASTAL-1" trial for major depressive disorder (MDD), with results indicating no significant difference from placebo in reducing …

Continue ›››

Profluent Unveils AI Model to Advance CRISPR-Cas Systems for Gene Editing

Profluent Bio, a Berkeley-based biotech founded in 2022, and funded with $44 million to date, has released an AI model aimed at advancing the design of CRISPR-Cas gene-editing systems. The …

Continue ›››

Calico's Small Molecule eIF2B Activator Falls Short in ALS Trial

Calico, the Alphabet-backed biotech focused on aging and longevity, has encountered a hurdle in its efforts to develop treatments for amyotrophic lateral sclerosis (ALS). Massachusetts General Hospital’s Healy ALS Platform …

Continue ›››

Insilico Medicine Reports Positive Results from Phase I Trials of ISM5411, an AI-Designed Drug for Inflammatory Bowel Disease

Insilico Medicine announced favorable outcomes from two Phase I clinical trials of ISM5411, a gut-restricted PHD1/2 inhibitor designed for inflammatory bowel disease (IBD). Conducted in Australia and China, the trials …

Continue ›››